LataMed AI Corp. (OTC: LMED) announced today that it expects to submit a corporate action request to FINRA for approval of a proposed five-for-one forward stock split, along with proportional increases in authorized common and preferred stock. The move is intended to support the company's long-term operational scalability, strategic flexibility, and future growth initiatives as it advances telehealth infrastructure and healthcare analytics platforms in Latin America and other emerging markets.
The proposed forward stock split would apply to all issued and outstanding shares of common stock and outstanding preferred stock designations, including the Series C Voting Preferred Stock. The company emphasized that the action does not involve debt restructuring, recapitalization, or reduction in shareholder ownership percentages. No fractional shares are expected to be issued; any fractional interests would be rounded up to the nearest whole share.
Management stated that the forward stock split is part of a broader effort to align the company's capital structure with its transition into digital healthcare infrastructure and AI-driven telehealth operations. Dr. Kevin Rodan Levy, CEO of LataMed AI Corp., commented, “As we continue advancing our operational and commercialization initiatives throughout Latin America, we believe this proposed forward stock split and proportional capital structure expansion may support broader long-term strategic flexibility, operational scalability, and future growth initiatives as we continue building our healthcare technology platform.”
The company recently commenced initial operational activities for its telehealth platform in Venezuela, following regulatory authorization from the Ministerio del Poder Popular para la Salud and Servicio Autonomo de Contraloria Sanitaria (SACS). This marks a significant step in LataMed's expansion into emerging markets, where the company aims to provide scalable telehealth solutions.
The proposed forward stock split remains subject to FINRA review and approval, as well as completion of applicable regulatory processing and final corporate implementation procedures. The company cautioned that no assurance can be provided regarding the timing or ultimate effectiveness of the proposed corporate action.
LataMed AI Corp. is a development-stage digital health and AI technology company focused on telehealth infrastructure and healthcare analytics for emerging markets. The company has not yet generated revenues from its current business operations. More information is available at https://latamed.ai and through the company's SEC filings at www.sec.gov.
